Mitoxantrone and abacavir: An ALK protein-targeted < i > in silico < /i > proposal for the treatment of non-small cell lung cancer
This study proposes FDA-approved drugs with ALK inhibitory characteristics. Moreover, we identified pharmacophores sites that can be tested with other pharmacological libraries.
Source: PLoS One - Category: Biomedical Science Authors: Juan Enrique Faya Castillo Source Type: research
More News: Biomedical Science | Cancer | Cancer & Oncology | Databases & Libraries | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Study | Translocation | Vitamin B2